The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 5, 2000, Pages 369-374

  Chen, Mei ^a   Hough, Amanda M ^a   Lawrence, Theodore S ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Apoptosis; Gemcitabine; p53; Radio sensitization

Indexed keywords

GEMCITABINE; PROTEIN BAX; PROTEIN P53; RADIOSENSITIZING AGENT;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL SURVIVAL; COLON CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; RADIOSENSITIZATION;

EID: 0034100255     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051004     Document Type: Article

References (42)

1. 1. Baker CH, Banzon J, Bollinger JM, et al (1991) 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J Med Chem 34: 1879-1884
2. 2. Canman C, Kastan M (1997) Role of p53 in apoptosis. Adv Pharmacol 41: 429-460
3. 3. Chen HH, Zhang J, Ling CC (1994) Transfected c-myc and c-Ha-ras modulate radiation-induced apoptosis in rat embryo cells. Radiat Res 139: 307-315
4. 4. Fan S, Smith ML, Rivet DJ, et al (1995) Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55: 1649-1654
5. 5. Fertil B, Dertinger H, Courdi A, et al (1984) Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radiat Res 99: 73-84
6. 6. Grasso L, Mercer W (1997) Pathways of p53-dependent apoptosis. Vitamins Hormones 53: 139-173
7. 7. Han J, Sabbatini P, Perez D, et al (1996) The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death promoting bax protein. Genes Dev 10: 461-477
8. 8. Hartwell LH, Kastan MB (1994) Cell cycle control and cancer. Science 266: 1821-1828
9. 9. Hoy CA, Seamer LC, Schimke RT (1989) Thermal denaturation of DNA for immunochemical staining of incorporated bromodeoxyuridine (BrdUrd): critical factors that affect the amount of fluorescence and the shape of BrdUrd/DNA histogram. Cytometry 10: 718-725
10. 10. Huang P, Plunkett W (1995) Fludarabine-and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 36: 181-188
11. 11. Innocente SA, Abrahamson JL, Cogswell JP, Lee JM (1999) p53 regulates a G2 checkpoint through cyclin B1. Proc Natl Acad Sci USA 96: 2147-2152
12. 12. Kastan MB, Onyekwere O, Sidransky D, Volgestein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311
13. 13. Kessis TD, Siebos RJ, Nelson WG, et al (1993) Human papillomavirus 16 E6 expression disrupts the p53-mediated response to DNA damage. Proc Natl Acad Sci USA 90: 3988-3992
14. 14. Kuerbitz SJ, Plunkett BS, Walsh WV, et al (1992) Wild type p53 is a cell cycle check point determinant following irradiation. Proc Natl Acad Sci USA 89: 7491-7495
15. 15. Lane D (1992) P53, guardian of the genome. Nature 358: 15-16
16. 16. Latz D, Fleckenstein K, Eble M, et al (1998) Radiosensitizing potential of gemcitabine (2′,2′-difluoro-2′-deoxycytidine within the cell cycle in vitro. Int J Radiat Oncol Biol Phys 41: 875-882
17. 17. Lawrence TS, Chang EY, Hahn TM, et al (1996) Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys 34: 867-872
18. 18. Lawrence TS, Chang EY, Hahn TM, et al (1997) Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine). Clin Cancer Res 3: 777-782
19. 19. Lawrence TS, Eisbruch A, Shewach D (1997) Gemcitabine-mediated radiosensitization. Suppl Semin Oncol 24: 24-28
20. 20. Lawrence TS, Eisbruch A, McGinn C, et al (1998) Radiosensitization by gemcitabine. Oncogenetics 24: 24-28
21. 21. Lawrence TS, Tepper JE, Blackstock AW (1998) Fluoropyrimidine-radiation interactions in cells and tumors. Semin Radiat Oncol 4: 260-266
22. 22. Lowe SW, Ruley HE, Jacks T, et al (1993) p53-dependent apoptosis modulates the cytotoxicity of anti-cancer agents. Cell 74: 947-967
23. 23. McCurrach M, Connor T, Knudson C, et al (1997) Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci USA 94: 2345-2349
24. 24. McGinn CJ, Shewach DS, Lawrence TS (1996) Radiosensitizing nucleosides. J Natl Cancer Inst 88: 1193-1203
25. 25. McGinn C, Smith D, Szarka C, et al (1998) A phase I study of gemcitabine in combination with radiation therapy in patients with localized unresectable pancreatic cancer. Proc Am Soc Cancer Oncol 17: 264a
26. 26. McIlwrath AJ, Vasey PA, Ross GM, et al (1994) Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res 54: 3718-3722
27. 27. Miyashita T, Krajewski S, Krajewski M, et al (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogenetics 9: 1799-1805
28. 28. Morgan SE, Kastan MB (1997) p53 and ATM: cell cycle, cell death, and cancer. Adv Cancer Res 71: 1-25
29. 29. Naida JD, Davis MA, Lawrence TS (1998) The effect of activation of wild type p53 function on fluoropyrimidine-mediated radiosensitization. Int J Radiat Oncol Biol Phys 41: 675-680
30. 30. O'Connor PM (1997) Mammalian G1 and G2 phase checkpoints. Cancer Surv 29: 151-182
31. 31. Oltvai Z, Milliman C, Korsmeyer S (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619
32. 32. Plunkett W, Huang P, Xu Y-Z, et al (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22 [Suppl 11]: S3-S10
33. 33. Ross DD, Cuddy DP (1994) Molecular effects of 2′,2′-difluorodeoxycytidine on DNA replication in intact HL-60 cells. Biochem Pharmacol 48: 1619-1630
34. 34. Sedlak T, Oltvai Z, Yang E, et al (1995) Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA 92: 7834-7838
35. 35. Selvakumaran M, Lin H, Miyashita T, et al (1994) Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways. Oncogene 9: 1791-1798
36. 36. Servomaa K, Kiuru A, Grenman R, et al (1996) p53 mutations associated with increased sensitivity to ionizing radiation in human head and neck cancer cell. Cell Prolif 29: 1649-1654
37. 37. Shewach D, Lawrence T (1995) Radiosensitization of human tumor cells by gemcitabine in vitro. Semin Oncol [Suppl] 22: 68-71
38. 38. Shewach DS, Hahn TM, Chang E, et al (1994) Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 54: 3218-3223
39. 39. Sinclair WK (1972) Sensitivity to mitotic delay and stage in the cycle. Curr Top Radiat Res 7: 323-327
40. 40. Tang H-Y, Davis MA, Strickfaden SM, et al (1994) Influence of cell cycle phase on radiation-induced cytotoxicity and DNA damage in human colon cancer (HT29) and Chinese hamster ovary cells. Radiat Res 138: S109-S112
41. 41. West CML, Keng PC, Sutherland RM (1988) Growth phase related variation in the radiation sensitivity of human colon adenocarcinoma cells. Int J Radiat Oncol Biol Phys 14: 1213-1219
42. 42. Yang S, Zhang X (1998) Masked radiosensitization by gemcitabine. Proc Radiat Res Soc 46: 181